REDHILL BIOPHARMA 1 RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHSun, 10 May 2026 14:04:54 +0200https://images.finanzen.net/images/finanzen_net_neu.gifREDHILL BIOPHARMA 1 RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netRedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side EffectsMon, 05 Jan 2026 13:00:00 +0100https://www.finanzen.net/nachricht/aktien/redhill-s-rhb-102-progresses-in-multiple-gi-indications-including-glp-1-therapy-related-gi-side-effects-15391987

RHB-1021 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, ...

]]>https://www.finanzen.net/nachricht/aktien/redhill-s-rhb-102-progresses-in-multiple-gi-indications-including-glp-1-therapy-related-gi-side-effects-15391987RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant CellsMon, 15 Dec 2025 13:00:00 +0100https://www.finanzen.net/nachricht/aktien/redhill-biopharma-s-positive-opaganib-results-indicate-reduction-in-venetoclax-resistant-cells-15358561

Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is ...

]]>https://www.finanzen.net/nachricht/aktien/redhill-biopharma-s-positive-opaganib-results-indicate-reduction-in-venetoclax-resistant-cells-15358561